A phase 3 trial found tirzepatide significantly reduced BMI in teens with obesity over 72 weeks, but most reported side effects and Zepbound is not FDA-approved for adolescents.
Zepbound Lowered Teens’ BMI 18.5% to 21.4% in 72-Week Trial, but Most Had Stomach Side Effects
by | Nov 16, 2026 | Uncategorized | 0 comments

Recent Comments